{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:26:07Z","timestamp":1793913967673,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The Phase 3 randomized controlled trial, TBTC Study 31\/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was 12-month tuberculosis disease free survival, while the primary safety outcome was the proportion of grade 3 or higher adverse events during the treatment period. We conducted an analysis of demographic, clinical, microbiologic, radiographic, and pharmacokinetic data and identified risk factors for unfavorable outcomes and adverse events. Among participants receiving the rifapentine-moxifloxacin regimen, low rifapentine exposure is the strongest driver of tuberculosis-related unfavorable outcomes (HR 0.65 for every 100\u2009\u00b5g\u2219h\/mL increase, 95%CI 0.54\u20130.77). The only other risk factors identified are markers of higher baseline disease severity, namely Xpert MTB\/RIF cycle threshold and extent of disease on baseline chest radiography (Xpert: HR 1.43 for every 3-cycle-threshold decrease, 95%CI 1.07\u20131.91; extensive disease: HR 2.02, 95%CI 1.07\u20133.82). From these risk factors, we developed a simple risk stratification to classify disease phenotypes as easier-, moderately-harder, or harder-to-treat TB. Notably, high rifapentine exposures are not associated with any predefined adverse safety outcomes. Our results suggest that the easier-to-treat subgroup may be eligible for further treatment shortening while the harder-to-treat subgroup may need higher doses or longer treatment.<\/jats:p>","DOI":"10.1038\/s41467-024-53273-7","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T19:02:08Z","timestamp":1730314928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Risk-stratified treatment for drug-susceptible pulmonary tuberculosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Vincent K.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie Z.","family":"Imperial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":false,"given":"Patrick P. J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo E.","family":"Vel\u00e1squez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina V.","family":"Kurbatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4710-925X","authenticated-orcid":false,"given":"Richard E.","family":"Chaisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-0476","authenticated-orcid":false,"given":"John L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Jindani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Whitworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kia E.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deron","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pheona","family":"Nsubuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Diacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Viet","family":"Nhung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":false,"given":"Radojka M.","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"AIDS Clinical Trial Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet Mayanja","family":"Kizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Ssaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Sekitoleko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Akol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Diacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Kleinhans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvetot","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jude Jean","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cadette","family":"Mercy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Apollon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertrude","family":"Royal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Mukwekwerere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeukai","family":"Musodza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred","family":"Gurupira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Tameris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique Kany Kany","family":"Luabeya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Camblart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Circ\u00e9e Phara","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Rassool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noluthando","family":"Mwelase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Bennet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lerato","family":"Mohapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ntebo","family":"Mogashoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetal","family":"Neverkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Lokhande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Munyanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Hosseinipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity","family":"Potani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha","family":"Okeyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Gurrion","family":"Ouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisca","family":"Rabuogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Escada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiane","family":"Tuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnstone","family":"Kumwenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Mponda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriette","family":"Hiemstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh G.","family":"Lalloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Siika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mey","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier R.","family":"Lama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Schwalb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Gotuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Sawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Tsikhutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivaporn","family":"Gatechompol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natthapol","family":"Kosashunhanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patcharaphan","family":"Sugandhavesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marineide Gon\u00e7alves","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita de Cassia","family":"Alves Lira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Luetkemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Coughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques H.","family":"Grosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Hosey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Podany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Borisov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"DeCausey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Fagley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Hedges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Hott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Jeffries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Mangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Peddareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Posey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Reichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ricaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Willby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April C.","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Tuberculosis Trials Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien T.","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh T. T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hue T. M.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyndy","family":"Merrifield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matebogo","family":"Xaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Jaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitumetse","family":"Majoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok-Chiu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Chiu","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polo","family":"Pavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Rogelio","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Burzynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mascha","family":"Elskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"53273_CR1","doi-asserted-by":"publisher","first-page":"105938","DOI":"10.1016\/j.cct.2020.105938","volume":"90","author":"SE Dorman","year":"2020","unstructured":"Dorman, S. E. et al. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31\/ACTG A5349 phase 3 clinical trial. Contemp. Clin. Trials 90, 105938 (2020).","journal-title":"Contemp. Clin. Trials"},{"key":"53273_CR2","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman, S. E. et al. Four-month Rifapentine regimens with or without Moxifloxacin for Tuberculosis. N. Engl. J. Med 384, 1705\u20131718 (2021).","journal-title":"N. Engl. J. Med"},{"key":"53273_CR3","unstructured":"World Health Organization. Treatment of Drug-Susceptible Tuberculosis: Rapid Communication. (World Health Organization, Geneva, 2021)."},{"key":"53273_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","volume":"71","author":"W Carr","year":"2022","unstructured":"Carr, W. et al. Interim Guidance: 4-Month Rifapentine-Moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis \u2014 United States, 2022. MMWR Morb. Mortal. Wkly Rep. 71, 285\u2013289 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"53273_CR5","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"53273_CR6","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","volume":"24","author":"MZ Imperial","year":"2018","unstructured":"Imperial, M. Z. et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat. Med. 24, 1708\u20131715 (2018).","journal-title":"Nat. Med."},{"key":"53273_CR7","doi-asserted-by":"crossref","unstructured":"Lange, C. et al. Perspective for Precision Medicine for Tuberculosis. Front. Immunol. 11, 566608 (2020).","DOI":"10.3389\/fimmu.2020.566608"},{"key":"53273_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1164\/rccm.202101-0117OC","volume":"204","author":"MZ Imperial","year":"2021","unstructured":"Imperial, M. Z., Phillips, P. P. J., Nahid, P. & Savic, R. M. Precision-enhancing risk stratification tools for selecting optimal treatment durations in tuberculosis clinical trials. Am. J. Respir. Crit. Care Med 204, 1086\u20131096 (2021).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"53273_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2104535","volume":"386","author":"A Turkova","year":"2022","unstructured":"Turkova, A. et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N. Engl. J. Med. 386, 911\u2013922 (2022).","journal-title":"N. Engl. J. Med."},{"key":"53273_CR10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1164\/rccm.201912-2489OC","volume":"202","author":"JE Hibma","year":"2020","unstructured":"Hibma, J. E. et al. Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 202, 866\u2013877 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"53273_CR11","unstructured":"Jindani, A. et al. Four-month high-dose rifampicin regimens for pulmonary tuberculosis. NEJM Evid. 2.9, EVIDoa2300054 (2023)."},{"key":"53273_CR12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1164\/rccm.200311-1612OC","volume":"169","author":"M Weiner","year":"2004","unstructured":"Weiner, M. et al. Pharmacokinetics of Rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. J. Respir. Crit. Care Med. 169, 1191\u20131197 (2004).","journal-title":"J. Respir. Crit. Care Med."},{"key":"53273_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1183\/13993003.01285-2015","volume":"47","author":"EPM van der Burgt","year":"2016","unstructured":"van der Burgt, E. P. M. et al. End TB with precision treatment! Eur. Respir. J. 47, 680\u2013682 (2016).","journal-title":"Eur. Respir. J."},{"key":"53273_CR14","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1183\/13993003.00040-2016","volume":"47","author":"S Ghimire","year":"2016","unstructured":"Ghimire, S. et al. Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. Eur. Respir. J. 47, 1867\u20131869 (2016).","journal-title":"Eur. Respir. J."},{"key":"53273_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","volume":"17","author":"MJ Boeree","year":"2017","unstructured":"Boeree, M. J. et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect. Dis. 17, 39\u201349 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"53273_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40262-019-00764-2","volume":"58","author":"AA Abulfathi","year":"2019","unstructured":"Abulfathi, A. A. et al. Clinical pharmacokinetics and pharmacodynamics of Rifampicin in human tuberculosis. Clin. Pharmacokinet. 58, 1103\u20131129 (2019).","journal-title":"Clin. Pharmacokinet."},{"key":"53273_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","volume":"198","author":"GE Vel\u00e1squez","year":"2018","unstructured":"Vel\u00e1squez, G. E. et al. Efficacy and safety of high-dose Rifampin in pulmonary tuberculosis. a randomized controlled trial. Am. J. Respir. Crit. Care Med. 198, 657\u2013666 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"53273_CR18","doi-asserted-by":"publisher","first-page":"e0213718","DOI":"10.1371\/journal.pone.0213718","volume":"14","author":"C Seijger","year":"2019","unstructured":"Seijger, C. et al. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. PLOS ONE 14, e0213718 (2019).","journal-title":"PLOS ONE"},{"key":"53273_CR19","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/clpt.2011.323","volume":"91","author":"KE Dooley","year":"2012","unstructured":"Dooley, K. E. et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug Rifapentine in healthy volunteers. Clin. Pharmacol. Ther. 91, 881\u2013888 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"53273_CR20","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1086\/428055","volume":"41","author":"RC Owens","year":"2005","unstructured":"Owens, R. C. & Ambrose, P. G. Antimicrobial safety: focus on Fluoroquinolones. Clin. Infect. Dis. 41, S144\u2013S157 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"53273_CR21","first-page":"276","volume":"53","author":"VR Aber","year":"1978","unstructured":"Aber, V. R. & Nunn, A. J. Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy. Bull. Int Union Tuberc. 53, 276\u2013280 (1978).","journal-title":"Bull. Int Union Tuberc."},{"key":"53273_CR22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00408-020-00398-3","volume":"198","author":"MdeM Pires","year":"2020","unstructured":"Pires, MdeM. et al. Association of Xpert MTB\/RIF cycle threshold values with tuberculosis treatment outcomes. Lung 198, 985\u2013989 (2020).","journal-title":"Lung"},{"key":"53273_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","volume":"191","author":"SE Dorman","year":"2015","unstructured":"Dorman, S. E. et al. Daily Rifapentine for treatment of pulmonary tuberculosis. a randomized, dose-ranging trial. Am. J. Respir. Crit. Care Med. 191, 333\u2013343 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"53273_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cpt.634","volume":"102","author":"R Savic","year":"2017","unstructured":"Savic, R. et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Clin. Pharmacol. Ther. 102, 321\u2013331 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"53273_CR25","doi-asserted-by":"publisher","first-page":"e044687","DOI":"10.1136\/bmjopen-2020-044687","volume":"11","author":"LS Peetluk","year":"2021","unstructured":"Peetluk, L. S. et al. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open 11, e044687 (2021).","journal-title":"BMJ Open"},{"key":"53273_CR26","doi-asserted-by":"publisher","first-page":"e71116","DOI":"10.1371\/journal.pone.0071116","volume":"8","author":"RS Wallis","year":"2013","unstructured":"Wallis, R. S., Wang, C., Meyer, D. & Thomas, N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS ONE 8, e71116 (2013).","journal-title":"PLoS ONE"},{"key":"53273_CR27","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMsr077003","volume":"357","author":"R Wang","year":"2007","unstructured":"Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J. & Drazen, J. M. Statistics in medicine \u2014 reporting of subgroup analyses in clinical trials. N. Engl. J. Med. 357, 2189\u20132194 (2007).","journal-title":"N. Engl. J. Med."},{"key":"53273_CR28","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.eclinm.2021.101250","volume":"43","author":"L Asadi","year":"2022","unstructured":"Asadi, L. et al. How much do smear-negative patients really contribute to tuberculosis transmissions? Re-examining an old question with new tools. eClinicalMedicine 43, 101250 (2022).","journal-title":"eClinicalMedicine"},{"key":"53273_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1774-8","volume":"8","author":"LSG Linguissi","year":"2015","unstructured":"Linguissi, L. S. G. et al. Diagnosis of smear-negative pulmonary tuberculosis based on clinical signs in the Republic of Congo. BMC Res. Notes 8, 804 (2015).","journal-title":"BMC Res. Notes"},{"key":"53273_CR30","unstructured":"US Food and Drug Administration. \u201cPopulation pharmacokinetics guidance for industry.\u201d US Food And Drug Administration (FDA): White Oak, MD, USA (2022)."},{"key":"53273_CR31","unstructured":"US Department of Health and Human Services. \u2018Common terminology criteria for adverse events (CTCAE) version 4.0.\u2019 National Institutes of Health, National Cancer Institute 4.03 (2009)."},{"key":"53273_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","volume":"371","author":"SH Gillespie","year":"2014","unstructured":"Gillespie, S. H. et al. Four-month Moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577\u20131587 (2014).","journal-title":"N. Engl. J. Med."},{"key":"53273_CR33","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","volume":"371","author":"A Jindani","year":"2014","unstructured":"Jindani, A. et al. High-dose Rifapentine with Moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med. 371, 1599\u20131608 (2014).","journal-title":"N. Engl. J. Med."}],"updated-by":[{"DOI":"10.1038\/s41467-025-59791-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53273-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53273-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53273-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:54:29Z","timestamp":1747202069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53273-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53273"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-53273-7","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-025-59791-2","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-025-59791-2","URL":"https:\/\/doi.org\/10.1038\/s41467-025-59791-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authorship team members have declared no potential conflicts of interest with respect to the research, authorship, or publication of this article. Sanofi commercial interests did not influence the study design; the collection, analysis, or interpretation of data; the preparation of this manuscript; or the decision to submit this manuscript for publication. A Sanofi technical expert served on the protocol team.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9400"}}